분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2017-07-25 19:08:04 , Hit : 1087
 CRISPR Structure Data Reveal How Cas Enzymes Choose Target

http://www.genengnews.com/gen-news-highlights/crispr-structure-data-reveal-how-cas-enzymes-choose-target/81254692?utm_medium=newsletter&utm_source=GEN+Daily+News+Highlights&utm_content=01&utm_campaign=GEN+Daily+News+Highlights_20170721


GEN News Highlights
More »
July 20, 2017

New data from Jennifer Doudna, Ph.D., co-pioneer of the CRISPR/Cas9 genome-editing technology, and her research group at the University of California, Berkeley show that for bacterial adaptive immunity to achieve site-selective expansion, the CRISPR integration complex relies on structural DNA cues rather than direct sequence recognition. The research team looked specifically at the Cas1-Cas2 enzymes and how they integrate viral DNA into a host's genome, creating a kind of molecular file that can be referenced later, during subsequent infections, to facilitate targeted counterattacks. Findings from the new study were published recently in Science through an article entitled “Structures of the CRISPR Genome Integration Complex.”

These proteins rely on the unique flexibility of the CRISPR DNA to recognize it as the site where viral DNA should be inserted, ensuring that "memories" of prior viral infections are properly stored. Lead study investigator Addison Wright, a graduate student in Dr. Doudna’s lab, told GEN “the discovery that recognition depends more on structure than direct sequence recognition has some pretty significant implications for the repurposing of Cas1-Cas2 as a tool. Their most obvious functions take advantage of their evolved role as a sort of information storage device, as we saw with George Church's recent work encoding a movie in E. coli genomes.”

Importantly, the investigators found that a third protein, called integration host factor (IHF), binds near the insertion site and bends the DNA into a U-shape, allowing Cas1-Cas2 to bind two recognition sites simultaneously. Moreover, the researchers discovered that the reaction requires target DNA to bend and partly unwind, something that only occurs at the appropriate target site.

CRISPR is an acronym that stands for clustered regularly interspaced short palindromic repeats, which refers to the unique region of DNA where snippets of viral DNA are stored for future reference—allowing the cell to recognize any virus that tries to reinfect. The viral DNA alternates with short palindromic repeats, which serve as the recognition signal to direct Cas1-Cas2 to add new viral sequences. Specific recognition of these repeats by Cas1-Cas2 restricts integration of viral DNA to the CRISPR array, allowing it to be used for immunity and avoiding the potentially fatal effects of inserting viral DNA in the wrong place.

In contrast to DNA-binding proteins that directly "read out" the nucleotides of their recognition sequence, Cas1-Cas2 recognizes the CRISPR repeat through more indirect means: its shape and flexibility. In addition to coding for proteins, the nucleotide sequence of a stretch of DNA also determines the molecule's physical properties, with some sequences acting as flexible hinges and others forming rigid rods. The sequence of the CRISPR repeat allows it to bend and flex in just the right way to be bound by Cas1-Cas2, allowing the protein complex to recognize its target by shape.

The discovery of how Cas1-Cas2 recognizes its target opens the door for modification of the proteins themselves. By tweaking the proteins, researchers might be able to create complexes that could be redirected to sequences other than the CRISPR repeat. Such complexes could be useful in organisms that lack their own CRISPR locus.

“The fact that recognition depends on the structure of the DNA changes how we go about looking for potential target sites,” Mr. Wright pointed out in correspondence to GEN. “Rather than looking for sequences that have a G at position 4, for example, we might look for ones that have a potential 'hinge' sequence in the middle.”

Wright concluded that “we might want to alter the proteins themselves to target them to a new system. Since recognition seems so dependent on the overall structure of the complex, the best strategy would be to make mutations over the protein as a whole, with the aim of subtly altering active site positioning, rather than focusing mutations at a particular sequence-readout region of the protein.”







1087   microRNA가 췌장암 치료제가 될 수 있을까  이성욱 2015/06/30 1052
1086   Drug flushes out hidden AIDS virus  이성욱 2015/03/07 1055
1085   융합연구리뷰 | Convergence Research Review  이성욱 2016/01/08 1057
1084   [바이오토픽] 브로드 연구소, 열띤 CRISPR 특허전쟁에서 승리  이성욱 2017/02/16 1060
1083   정밀의학의 끝: 개인화된 종양백신을 개발하는 과학자들  이성욱 2016/04/26 1061
1082   유전자치료제 연구개발 및 규제 동향 2015-식품의약품안전처  이성욱 2016/01/20 1066
1081   Gilead hepatitis C drug highly effective in cirrhosis patients  이성욱 2014/11/14 1068
1080   [바이오토픽] C형간염을 3주 만에 치료하는 DAA 3제요법  이성욱 2015/11/02 1070
1079   미국 과학·공학·의학 아카데미, 「GM 베이비」의 진행방향에 대한 윤곽 발표  이성욱 2017/02/16 1073
1078   진화와 질병치료 연구를 진전시킬 새로운 유전 메커니즘  이성욱 2015/02/06 1074
1077   일본의 검증팀 STAP 세포 재현 포기, 오보카타 사임  이성욱 2014/12/23 1075
1076   세계 20여 개국 과학자들, 유전자편집 정상회담 개최  이성욱 2015/12/05 1079
  CRISPR Structure Data Reveal How Cas Enzymes Choose Target  이성욱 2017/07/25 1087
1074   암 생존율을 높일 수 있는 면역세포  이성욱 2014/12/16 1091
1073   옥스포드 나노포어, 휴대용 시퀀서 미니온 출시 임박  이성욱 2015/05/08 1091
1072   Chinese Scientists To Test Gene Modifying Technique ‘CRISPR’ On Humans For The First Time  이성욱 2016/07/27 1095
1071   네안데르탈인과 이웃에 살았던 현생인류의 두개골 발견  이성욱 2015/02/03 1096
1070   [미국] 유전자가위 규제 마련 지연과 기업들의 움직임  이성욱 2016/07/21 1104
1069   유전자편집치료에 희망을 준 백혈병치료  이성욱 2015/11/11 1107
1068   인류의 역사를 고스란히 보여주는 결핵균의 게놈  이성욱 2015/01/21 1110

[1][2][3][4][5][6][7][8][9] 10 ..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN